Overview
Poly(2-oxazoline) (POx) is a very promising candidate for the use in polymer therapeutics. Amphiphilic POx triblock copolymers can be used as high capacity drug delivery systems for hydrophobic drugs, such as paclitaxel, and exhibit synergistic effects for the delivery of multiple chemotherapeutics. In this webinar, Prof. Jordan highlights the unparalleled high drug-loading capacities of POx systems, the polymer structural variability, and outline the consequences of the drug loading on the drug delivery system morphology.
What Will You Learn?
- Properties and advantages of polyoxazolines
- Methods for drug formulation with polyoxazolines
- Drug loading in polyoxazolines-based drug delivery systems
- Application of polyoxazoline drug delivery systems (cancer)
Who Should Watch?
- Pharmaceutical Scientists
- Biomedical Engineers
- Medicinal Chemists
- Polymer Chemists
- Drug Delivery Researchers
Speaker
Dr. Rainer Jordan
Technische Universität Dresden, Dresden, Germany
Chair of Macromolecular Chemistry, School of Science
Dr. Rainer Jordan studied chemistry at the University of Mainz, Germany and as an IAS fellow under Prof. T. Saegusa at Kyoto University, Japan. He joined Prof. K.K. Unger’s group in Mainz and worked as a PROCOPE fellow at C.N.R.S. Paris. In 1996, he obtained his doctoral degree in Chemistry under Prof. Unger from the University of Mainz. After his postdoctoral work under Prof. Ulman at the Polytechnic University in Brooklyn, NY, USA, he was appointed Assistant Professor at the same university. He returned to Germany and joined the group of Prof. O. Nuyken at the Technische Universität München for Habilitation. In 2009, he became full Professor, and Chair of Macromolecular Chemistry at the Technische Universität Dresden, Germany. His research interests include polymer chemistry, surface chemistry, self-assembly, biomimetic systems, nanoscience, and nanomedicine.
Materials science and engineering
- Drug delivery
Dauer:34min
Sprache:English
Sitzung 1:vorgestellt October 21, 2015
Um weiterzulesen, melden Sie sich bitte an oder erstellen ein Konto.
Sie haben kein Konto?